Matthew P Fraser

US Patent:

7041704, May 9, 2006

Filed:

Feb 11, 2005

Appl. No.:

11/057024

Inventors:

Edward C. Burgard - Chapel Hill NC, US
Steven B. Landau - Wellesley MA, US
Matthew Oliver Fraser - Apex NC, US

Assignee:

Dynogen Pharmaceuticals, Inc. - Boston MA

International Classification:

A61K 33/18
A61K 31/45
A61K 31/04

US Classification:

514727, 514729, 514741

Abstract:

The invention relates to methods of using sodium channel modulators, particularly TTX-R sodium channel modulators and/or activity dependent sodium channel modulators to treat a gastrointestinal tract disorders, particularly inflammatory bowel disorders and irritable bowel syndrome.

US Patent:

7084116, Aug 1, 2006

Filed:

Mar 10, 2004

Appl. No.:

10/796952

Inventors:

Matthew Oliver Fraser - Apex NC, US
Karl Bruce Thor - Morrisville NC, US
Edward C. Burgard - Chapel Hill NC, US

Assignee:

Dynogen Pharmaceuticals, Inc. - Boston MA

International Classification:

A61K 38/12
A61K 38/00

US Classification:

514 9, 530300

Abstract:

The invention relates to methods of using Cav2. 2 subunit calcium channel modulators to treat painful and non-painful lower urinary tract disorders and the related genitourinary tract disorders vulvodynia and vulvar vestibulitis in normal and spinal cord injured patients.

US Patent:

7125848, Oct 24, 2006

Filed:

Jun 10, 2004

Appl. No.:

10/865225

Inventors:

Matthew Oliver Fraser - Apex NC, US
Steven B. Landau - Wellesley MA, US
Edward C. Burgard - Chapel Hill NC, US

Assignee:

Dynogen Pharmaceuticals, Inc. - Boston MA

International Classification:

A01N 37/18
A61K 38/00
C07K 14/00

US Classification:

514 12, 514 2, 530350

Abstract:

A method is provided for using Cav2. 2 subunit calcium channel modulators to treat non-inflammatory gastrointestinal tract disorders.

US Patent:

7223754, May 29, 2007

Filed:

Nov 17, 2004

Appl. No.:

10/990843

Inventors:

Matthew Oliver Fraser - Apex NC, US
Karl Bruce Thor - Morrisville NC, US
Edward C. Burgard - Chapel Hill NC, US

Assignee:

Dynogen Pharmaceuticals, Inc. - Waltham MA

International Classification:

A61K 31/54

US Classification:

5142268, 5142272, 544 54

Abstract:

The invention relates to methods of using Cav2. 2 subunit calcium channel modulators, particularly thiazolidinone, oxazolidinone, and imidazolone derivatives, to treat lower urinary tract and related disorders.

US Patent:

7459430, Dec 2, 2008

Filed:

Jun 8, 2006

Appl. No.:

11/449489

Inventors:

Matthew Oliver Fraser - Apex NC, US
Karl Bruce Thor - Morrisville NC, US
Edward C. Burgard - Chapel Hill NC, US

Assignee:

Dynogen Pharmaceuticals, Inc. - Boston MA

International Classification:

A61K 38/12

US Classification:

514 9, 530300

Abstract:

The invention relates to methods of using Cav2. 2 subunit calcium channel modulators to treat painful and non-painful lower urinary tract disorders and the related genitourinary tract disorders vulvodynia and vulvar vestibulitis in normal and spinal cord injured patients.

US Patent:

20040142034, Jul 22, 2004

Filed:

Dec 19, 2003

Appl. No.:

10/741360

Inventors:

Karl Thor - Morrisville NC, US
Edward Burgard - Chapel Hill NC, US
Matthew Fraser - Apex NC, US

Assignee:

Dynogen Pharmaceuticals, Inc. - Boston MA

International Classification:

A61K009/22

US Classification:

424/468000

Abstract:

A method is provided for treatment of non-painful bladder disorders, particularly non-painful overactive bladder without loss of urine. The method comprises administration of an subunit calcium channel modulator, including gabapentin, pregabalin, GABA analogs, fused bicyclic or tricyclic amino acid analogs of gabapentin, amino acid compounds, and other compounds that interact with the calcium channel subunit.

US Patent:

20040198822, Oct 7, 2004

Filed:

Mar 22, 2004

Appl. No.:

10/805977

Inventors:

Matthew Fraser - Apex NC, US
Karl Thor - Morrisville NC, US
Edward Burgard - Chapel Hill NC, US
Lee Brettman - Sudbury MA, US
Steven Landau - Wellesley MA, US
Daniel Ricca - Rougemont NC, US

Assignee:

Dynogen Pharmacueticals, Inc. - Boston MA

International Classification:

A61K031/195

US Classification:

514/561000

Abstract:

A method is provided for using subunit calcium channel modulators or other compounds that interact with the calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, 3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

US Patent:

20040209960, Oct 21, 2004

Filed:

Jan 30, 2004

Appl. No.:

10/769072

Inventors:

Edward Burgard - Chapel Hill NC, US
Karl Thor - Morrisville NC, US
Matthew Fraser - Apex NC, US

Assignee:

Dynogen Pharmaceuticals, Inc. - Boston MA

International Classification:

A61K031/137

US Classification:

514/649000

Abstract:

The invention relates to methods of using sodium channel modulators, particularly TTX-R sodium channel modulators and/or activity dependent sodium channel modulators to treat painful and non-painful lower urinary tract disorders, particularly painful and non-painful overactive bladder with and/or without loss of urine.